Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage pharmaceutical company dedicated to developing novel therapies for neurodegenerative diseases such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Headquartered in Malvern, Pennsylvania, Annovis is pioneering innovative approaches to combat neurodegeneration by targeting multiple neurotoxic proteins simultaneously. The company’s lead compound, Buntanetap (formerly Posiphen or ANVS401), is designed to inhibit the formation of amyloid beta, tau, alpha-synuclein, and TDP43, aiming to improve synaptic transmission and axonal transport while reducing neuroinflammation.
Annovis Bio’s flagship product, Buntanetap, is in phase II/III clinical trials for the treatment of mild to moderate AD and early PD. The drug has shown promising results, demonstrating significant improvements in cognitive function and reducing neurotoxic biomarkers in patients. Alongside Buntanetap, the company is advancing ANVS405 for acute neurodegeneration post-traumatic brain injury and stroke, and ANVS301, currently in phase I trials, aimed at enhancing cognitive capabilities in advanced AD and dementia.
Founded in 2008 by Dr. Maria Maccecchini, Ph.D., Annovis Bio continues to focus on restoring brain function to alleviate symptoms and improve the quality of life for individuals affected by neurodegenerative diseases. The company has established itself as a leader in the field through partnerships, rigorous scientific research, and a commitment to transparency with all stakeholders.
Recent achievements include the completion of a Phase II/III study of Buntanetap in Alzheimer’s patients, demonstrating a statistically significant improvement in cognition and a favorable safety profile. Additionally, Annovis has filed a patent application for the use of Buntanetap in treating neuropsychiatric conditions such as autism and bipolar disorder, highlighting the drug’s versatile potential.
A financial overview reveals that Annovis ended the first quarter of 2024 with $3.1 million in cash, ensuring operational sustainability into the fourth quarter through strategic financial management. The company has actively engaged with the scientific and investment communities, participating in notable conferences like the International Conference on Alzheimer’s and Parkinson’s Diseases and hosting investor calls to discuss clinical milestones and future plans.
For more information about Annovis Bio, visit their website and follow them on LinkedIn and X (formerly Twitter).
Annovis Bio, Inc. (NYSE: ANVS) announced the approval for 48 additional clinical trial sites across five European Union countries for its ongoing Phase 3 study of buntanetap aimed at treating Parkinson's disease. The new sites will enhance patient recruitment for the study, which currently has 50 sites open in the United States. The Company expects to conduct an interim analysis in Q2 2023, based on the enrollment of patients who have completed two months of therapy. Preliminary Phase 2a data showed promising results, with statistically significant improvements observed in motor function and cognition without significant adverse events.
Annovis Bio, Inc. (NYSE: ANVS) has filed a patent application expanding its drug platform from neurodegenerative to neuropsychiatric indications, specifically focusing on mental illnesses like autism, ADHD, bipolar disorder, major depressive disorder, and schizophrenia. The patent proposes treatment methods using buntanetap and its analogs, which have shown potential in Phase 2a trials for cognitive improvements in Alzheimer's and Parkinson's patients. The company aims to leverage its existing patents in neurodegenerative diseases to broaden its intellectual property portfolio, enhancing its market position and therapeutic reach.
Annovis Bio (NYSE: ANVS) announced strong enrollment in its Phase 3 trial of buntanetap for Parkinson's disease, with an interim analysis expected in Q2 2023. This trial aims to evaluate the safety and efficacy of buntanetap in early-stage patients, featuring a randomized, double-blind, placebo-controlled design. The study enrolls patients receiving either 10mg or 20mg of buntanetap or a placebo for six months. Early Phase 2a data indicated significant improvements in motor function with no adverse events. The trial is designed to confirm optimal patient enrollment figures, potentially adjusting the target number based on efficacy observations.
On January 6, 2023, Annovis Bio, Inc. (NYSE: ANVS) announced the appointment of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology. These additions aim to strengthen the company's capabilities in clinical trials and regulatory navigation, especially for their late-stage trials in Alzheimer’s and Parkinson’s diseases. Dr. Christie brings over 40 years of pharma experience, while Mr. Prohaska offers 25 years in preclinical drug development. These leadership changes are expected to enhance Annovis's large-scale manufacturing and product development efforts.
Annovis Bio, Inc. (NYSE: ANVS) announced its third quarter 2022 financial results, highlighting progress in clinical trials for buntanetap in Parkinson's and Alzheimer's diseases. The FDA authorized a Phase 3 trial for early Parkinson's patients and a Phase 2/3 trial for moderate Alzheimer's patients. Annovis reported a net loss of $7.6 million for the quarter, an increase from $2.9 million in Q3 2021. Cash reserves stand at $32 million as of September 30, 2022. The company also published three new patents and appointed a new CFO, which strengthens its intellectual property portfolio and financial leadership.
Annovis Bio (NYSE: ANVS) announced its participation in the ThinkEquity 2022 Investor Conference scheduled for October 26, 2022, in New York City. The presentation will take place from 9:00 am ET to 9:30 am ET at The Mandarin Oriental Hotel. Investors can access the webcast [here](https://wsw.com/webcast/tep23/anvs/1687376). Annovis Bio is advancing its drug candidate, Buntanetap, which targets neurodegenerative diseases such as Alzheimer's and Parkinson's. The company is conducting Phase 3 studies for early Parkinson's and Phase 2/3 for Alzheimer's patients.
Annovis Bio, Inc. (NYSE: ANVS) announced the publication of Phase 2a clinical study data for its drug, buntanetap, in The Journal of Prevention of Alzheimer's Disease. The study indicates that buntanetap was well-tolerated and demonstrated significant improvements in cognition for Alzheimer's patients and motor functions for Parkinson's patients. The company is advancing to Phase 3 clinical trials for early Parkinson's and has received FDA authorization for a Phase 2/3 study in moderate Alzheimer's. Buntanetap is positioned as a potential disease-modifying therapy.
On October 6, 2022, Annovis Bio (NYSE: ANVS) announced FDA authorization for its Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD). The approval follows a successful Phase 2a trial showing significant cognitive improvements in AD patients. Following this positive outcome, Annovis aims to advance buntanetap as a treatment for neurodegenerative disorders like AD and Parkinson's Disease (PD). The drug functions as a translational inhibitor of neurotoxic proteins, indicating its potential in treating various neurodegenerative conditions.
On September 29, 2022, Annovis Bio (NYSE: ANVS) announced its participation at the Ladenburg Thalmann Healthcare Conference in New York City. The presentation is scheduled for 12:30 p.m. to 12:55 p.m. Eastern Time at the Sofitel Hotel. Annovis is developing buntanetap, an innovative treatment for neurodegenerative diseases, which has shown promise in clinical trials. The company aims to address conditions like Alzheimer's and Parkinson's diseases. Investors can arrange one-on-one meetings through their Ladenburg Thalmann representatives.
On September 13, 2022, Annovis Bio (NYSE: ANVS) announced the publication of three US patents related to its platform drug, buntanetap, which targets neurodegenerative diseases such as ALS, Huntington's, and prion diseases. These patents, valid until 2031, enhance the company's intellectual property in a competitive market. The press release highlights buntanetap's potential, demonstrating safety and efficacy in clinical trials for Alzheimer's and Parkinson's, paving the way for ongoing studies and commercialization opportunities.
FAQ
What is the current stock price of Annovis Bio (ANVS)?
What is the market cap of Annovis Bio (ANVS)?
What is Annovis Bio, Inc.?
What is Buntanetap?
Where is Annovis Bio headquartered?
Who founded Annovis Bio?
What are the key focus areas for Annovis Bio?
What recent achievements has Annovis Bio accomplished?
What are the financial highlights for Annovis Bio?
What is ANVS405?
What is ANVS301?
How can I learn more about Annovis Bio's developments?
